{"Symbol": "AUPH", "AssetType": "Common Stock", "Name": "Aurinia Pharmaceuticals Inc", "Description": "Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.", "CIK": "1600620", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "#140, 14315 ? 118 AVENUE, EDMONTON, AB, CANADA, T5L 4S6", "OfficialSite": "https://www.auriniapharma.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "1876091000", "EBITDA": "100551000", "PERatio": "25.41", "PEGRatio": "0", "BookValue": "2.774", "DividendPerShare": "None", "DividendYield": "None", "EPS": "0.56", "RevenuePerShareTTM": "1.941", "ProfitMargin": "0.293", "OperatingMarginTTM": "0.405", "ReturnOnAssetsTTM": "0.0941", "ReturnOnEquityTTM": "0.206", "RevenueTTM": "265808000", "GrossProfitTTM": "213077000", "DilutedEPSTTM": "0.56", "QuarterlyEarningsGrowthYOY": "1.3", "QuarterlyRevenueGrowthYOY": "0.084", "AnalystTargetPrice": "16.67", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "4", "AnalystRatingHold": "3", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "25.41", "ForwardPE": "18.48", "PriceToSalesRatioTTM": "7.06", "PriceToBookRatio": "5.13", "EVToRevenue": "6.03", "EVToEBITDA": "15.48", "Beta": "1.541", "52WeekHigh": "16.54", "52WeekLow": "6.55", "50DayMovingAverage": "15.24", "200DayMovingAverage": "11.96", "SharesOutstanding": "131841000", "SharesFloat": "127983000", "PercentInsiders": "6.823", "PercentInstitutions": "52.837", "DividendDate": "None", "ExDividendDate": "None"}